TEMPO
19.2.2018 12:16:03 CET | Business Wire | Press release
Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017.
“2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.”
Highlights for 2017 include:
- Revenue grew 38% year-over-year to US$17.9 million
- Almost 2,000 new customers were acquired
- Launched our new cloud infrastructure
- Expanded product footprint beyond the Atlassian environment with Tempo for Slack
- North American operations continued to grow
- More than 120 partners worldwide
- Celebrated our 10-year anniversary
Revenue improved by 38% year-over-year
Tempo’s annual earnings increased by 38% year-over-year to US$17.9 million, fueled by double-digit growth across all our deployment options and products. The Company’s client base is highly diversified across company size and industry sector, helping to stabilize Tempo’s revenue and protect against sector downturns.
New cloud platform
In 2017, with the migration of more than 7,000 customers, Tempo moved to hosting its own cloud environment. Which drew to close the major transition and investment that this 18-month project required.
The company has not only built new products and infrastructure to solidify the foundation of our cloud vision, but has also redesigned and established new processes as well as ways of working, transforming ourselves from software supplier to a world-class services company. Customers will benefit from improved performance and reduced latency on the Amazon Web Services Platform, and can expect to see more frequent product releases in response to emerging requirements.
Tempo for Slack
Tempo for Slack integrates its time management solution tightly within the chat platform allowing users expedited productivity and real-time reporting. Slack customers using Jira will be able to use Tempo to seamlessly track their time, receive notifications and reminders, as well as alerts to approve timesheets all within the same environment.
North America operation continues to expand
This year Tempo added 17 employees to our Montreal office, while maintaining a strong team at its headquarters in Iceland, bringing the total number of employees close to 100.
10-year anniversary and almost 2,000 new customers acquired
Tempo marked its 10-year anniversary and surpassed 10,000 customers in Q2 2017. This year saw further growth to almost 12,000 customers, since its launch almost a decade ago. Significant new clients including: Bank of Singapore, Airbus Defence and Space, Verizon, NBC Universal, Rolex and many others.
Over 120 partners worldwide
Collaborative growth is key to the strength of Tempo, and in 2017 our Atlassian Expert Partner network grew to a total of over 120 Partners worldwide. Tempo is looking forward to fostering and strengthening partnerships with both existing and potential partners as well as customers in 2018.
Other highlights:
- Launched Tempo for Chrome extension
- Launched a more powerful and custom time report for Tempo Cloud
- Donated over $105,000 to the non-profit Room to Read. Amount calculated from all proceeds of 10-user starter license sales. Room to Read seeks to improve literacy and gender equality in education in the developing world
- Renewed our participation in the Pledge 1% corporate philanthropy movement, founded by Atlassian, Salesforce, and Rally.
###
About Tempo
Tempo develops sophisticated software solutions that help make work easier and more efficient for software, IT services and core business teams. Tempo has over 11,000 customers worldwide, ranging from small startups to the largest global enterprises including Amazon, BMW, Pfizer, HomeAway, PayPal, Hulu, Dell, and Disney.
To learn more about Tempo, visit www.tempo.io .
Additional Resources
Follow the Tempo blog: http://blog.tempo.io
Follow us on Twitter: http://twitter.com/tempohq
Become a fan on Facebook: http://facebook.com/tempohq
Follow us on LinkedIn: https://www.linkedin.com/company/TempoHQ
View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005219/en/
Contact:
Media Contact:
Tempo
Agust Einarsson
CEO
ae@tempo.io
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom